Diiodohydroxyquinoline是一种口服有效的抗寄生虫药物，对SARS-CoV-2具有强抗病毒活性，但其在小鼠体内显示致突变性(可被抗坏血酸拮抗)，临床用于炎症性肠阿米巴病、阿米巴肝脓肿及慢性非特异性腹泻的研究。
| 英文别名 (English Synonym) | Diiodohydroxyquinoline |
| 中文名称 (Chinese Name) | 双碘喹啉；二碘羟基喹啉；二磺羟喹 |
| 靶点 (Target) | Anti-infection |
| 通路 (Pathway) | Microbiology |
| CAS号 (CAS NO.) | 83-73-8 |
| 分子式 (Formula) | C9H5I2NO |
| 分子量 (Molecular Weight) | 396.95 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Yuan S, Chan JFW, Chik KKH, Chan CCY, Tsang JOL, Liang R, Cao J, Tang K, Chen LL, Wen K, Cai JP, Ye ZW, Lu G, Chu H, Jin DY, Yuen KY. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol Res. 2020 Sep;159:104960. doi: 10.1016/j.phrs.2020.104960. Epub 2020 May 28. PMID: 32473310; PMCID: PMC7254006.
[2] Ghaskadbi S, Vaidya VG. In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline. Mutat Res. 1989 Mar;222(3):219-22. doi: 10.1016/0165-1218(89)90137-7. PMID: 2493578.
